Skip to main content

Table 4 Resistance rates of isolated pathogens

From: Epidemiology and risk factors for multi-drug resistant hospital-acquired urinary tract infection in patients with liver cirrhosis: single center experience in Serbia

ABs Enterococcus spp b Enterobacteriaceae Totala P value Overall
MDR (n = 12) Non-MDR (n = 22) MDR (n = 18) Non-MDR (n = 4) MDR (n = 35) Non-MDR (n = 30) n = 65
AMP 8/11 (72.7) 2/20 (10.0) 16/18(88.9) 4/4 (100) 29/34(85.3) 10/28 (35.7) 0.000 39/62 (62.9)
AMX 8/11 (72.7) 2/20 (10.0) 16/18(88.9) 4/4 (100) 29/34 (85.3) 9/27 (33.3) 0.000 38/61 (62.3)
AMP-SL 1/2 (50.0) 1/6 (50.0) 16/18(88.9) 4/4 (100) 8/12 (66.7) 3/8 (37.5) 0.362 11/20 (55.0)
AM-CL 7/9 (77.8) 2/14 (14.3) 16/18(88.9) 2/4 (50.0) 26/30(86.7) 7/22 (31.8) 0.000 33/52 (63.5)
P-TZ 2/2 (100) 0/2 (0) 5/13 (38.5) 1/3 (33.3) 9/17 (52.9) 1/7 (14.3) 0.172 10/24 (41.7)
MER 4/5 (80.0) 0/4 (0) 6/15 (40.0) 1/3 (33.3) 14/24(58.3) 1/9 (11.1) 0.021 15/33 (45.4)
IMI 6/7 (85.7) 1/6 (16.7) 5/13 (38.5) 0/3 (0) 16/25(64.0) 1/11 (9.1) 0.003 17/36(47.2)
ERT 4/4 (100) 0/4 (0) 8/13 (61.5) 1/2 (50.0) 17/22(77.3) 3/8 (37.5) 0.078 20/30 (66.7)
CFAZ 16/16 (100) 1/3 (33.3) 32/32 (100) 20/23 (86.9) 0.068 52/55 (94.5)
CEPH 18/18 (100) 1/4 (25.0) 35/35 (100) 21/25 (84.0) 0.026 56/60 (93.3)
CEFU 16/16 (100) 1/4 (25.0) 32/32 (100) 21/26 (80.8) 0.014 53/58 (91.4)
CEFO 16/17(94.1) 1/4 (25.0) 32/33(97.0) 21/25 (84.0) 0.154 53/58 (91.4)
CFTX 17/17 (100) 1/4 (25.0) 33/33 (100) 21/25 (84.0) 0.030 54/58 (93.1)
CFTA 18/18 (100) 1/3 (33.3) 33/34(97.0) 20/24 (83.3) 0.004 53/58 (91.4)
CEFP 18/18 (100) 1/4 (25.0) 33/34(97.0) 20/24 (83.3) 0.149 53/58 (91.4)
AMI 1/1 (100) 1/3 (33.3) 4/16 (25.0) 1/3 (33.3) 8/20 (40.0) 2/10 (20.0) 0.419 10/30 (33.3)
GEN 4/8 (50.0) 3/6 (50.0) 7/13 (53.8) 1/4 (25.0) 14/25(56.0) 4/12 (33.3) 0.295 18/37 (48.6)
CIP 11/11(100) 12/13 (92.3) 10/13(76.9) 1/4 (25.0) 23/26(88.5) 13/19 (68.4) 0.137 36/45 (80.0)
LEVO 1/1 (100) 2/2 (100) 3/3 (100) 1/3 (33.3) 5/5 (100) 3/7 (42.8) 0.081 8/12 (66.7)
VAN 5/12 (41.7) 2/21 (9.5) 1/5 (20.0) 1/1 (100) 7/20 (35.0) 3/23 (13.0) 0.148 10/43 (23.2)
TEI 7/12 (58.3) 1/21 (4.8) 1/5 (20.0) 1/1 (100) 10/19(52.6) 2/22 (9.1) 0.005 12/41 (29.3)
T-SX 1/2 (50.0) 2/4 (50.0) 1/5 (20.0) 1/1 (100) 19/24(79.2) 7/11 (63.6) 0.416 26/35 (74.3)
NIF 6/8 (75.0) 2/6 (33.3) 5/5 (100) 1/2 (50.0) 11/15(73.3) 3/8 (37.5) 0.179 14/23 (60.9)
LIN 1/4 (25.0) 0/5 (0) 1/7 (14.3) 1/1 (100) 1/7 (14.3) 1/7 (14.3) 1.000 2/14 (14.3)
TIG 1/3 (33.3) 0/3 (0) 0/1 (0) 1/2 (50.0) 1/6 (16.7) 1/5 (20.0) 1.000 2/11 (18.2)
  1. Notes: This table shows the resistance rates to most commonly used antibiotics in clinical practice with comparison between MDR and non MDR pathogens. b due to the intrinsic cephalosporin resistance, data are not shown for enterococci but are included in totals and the overall analysis. aAcinetobacter baumanii, Pseudomonas aeruginosa, Moraxella catarrhalis, methicillin-sensitive Staphylococcus aureus, methicillin-resistant Staphylococcus aureus included in analysis but not shown. ABs stands for antibiotics; AMP Ampicillin, AMX Amoxicillin, AMP-SL Ampicillin sulbactam, AM-CL Amoxicillin-clavulanic acid, P-TZ Piperacillin-tazobactam, MER Meropenem, IMI Imipenem, ERT Ertapenem, CFAZ Cefazolin, CEPH Cephalexin, CEFU Cefuroxime, CEFO Cefotaxime, CFTX Ceftriaxone, CFTA Ceftazidime, CEFP Cefepime, AMI Amikacin, GEN Gentamicin, CIP Ciprofloxacin, LEVO Levofloxacin, VAN Vancomycin, TEI Teicoplanin, T-SX Trimethoprim-sulfamethoxazole, NIF Nitrofurantoin, LIN Linezolid, and TIG Tigecycline